Department of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
BMJ Open. 2015 Jan 5;5(1):e006121. doi: 10.1136/bmjopen-2014-006121.
The c.2268dup mutation in the thyroid peroxidase (TPO) gene is the most common TPO alteration reported in Taiwanese patients with thyroid dyshormonogenesis. The ancestors of these patients are believed to originate from the southern province of China. Our previous study showed that this mutation leads to reduced abundance of the TPO protein and loss of TPO enzyme activity in a Malaysian-Chinese family with goitrous hypothyroidism. The aim of our study was to provide further data on the incidence of the c.2268dup mutation in a cohort of Malaysian-Chinese and its possible phenotypic effects.
Cohort study.
Twelve biologically unrelated Malaysian-Chinese patients with congenital hypothyroidism were recruited in this study. All patients showed high thyrotropin and low free thyroxine levels at the time of diagnosis with proven presence of a thyroid gland.
Screening of the c.2268dup mutation in the TPO gene in all patients was carried out using a PCR-direct DNA sequencing method.
Further screening for mutations in other exonic regions of the TPO gene was carried out if the patient was a carrier of the c.2268dup mutation.
The c.2268dup mutation was detected in 4 of the 12 patients. Apart from the c.2268dup and a previously documented mutation (c.2647C>T), two novel TPO alterations, c.670_672del and c.1186C>T, were also detected in our patients. In silico analyses predicted that the novel alterations affect the structure/function of the TPO protein.
The c.2268dup mutation was detected in approximately one-third of the Malaysian-Chinese patients with thyroid dyshormonogenesis. The detection of the novel c.670_672del and c.1186C>T alterations expand the mutation spectrum of TPO associated with thyroid dyshormonogenesis.
甲状腺过氧化物酶(TPO)基因中的 c.2268dup 突变是台湾地区甲状腺激素生成障碍患者最常见的 TPO 改变。这些患者的祖先是来自中国南方省份的移民。我们之前的研究表明,这种突变导致马来西亚-华裔甲状腺肿性甲状腺功能减退症家系中 TPO 蛋白丰度降低,TPO 酶活性丧失。本研究旨在进一步提供马来西亚-华裔人群中 c.2268dup 突变的发生率及其可能的表型效应数据。
队列研究。
本研究共纳入 12 例先天性甲状腺功能减退的无亲缘关系的马来西亚-华裔患者。所有患者在诊断时均表现为促甲状腺激素升高和游离甲状腺素降低,且均证实存在甲状腺。
采用 PCR 直接 DNA 测序法对所有患者的 TPO 基因 c.2268dup 突变进行筛查。
如果患者携带 c.2268dup 突变,则进一步筛查 TPO 基因其他外显子区域的突变。
在 12 例患者中发现 4 例存在 c.2268dup 突变。除了 c.2268dup 和之前记录的突变(c.2647C>T)外,还在我们的患者中发现了两种新的 TPO 改变,c.670_672del 和 c.1186C>T。计算机分析预测,新的改变会影响 TPO 蛋白的结构/功能。
在甲状腺激素生成障碍的马来西亚-华裔患者中,约三分之一存在 c.2268dup 突变。新型 c.670_672del 和 c.1186C>T 改变的检测扩大了与甲状腺激素生成障碍相关的 TPO 突变谱。